{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "6f0d7305",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import pandas as pd\n",
    "import sys\n",
    "\n",
    "sys.path.append(\"../../\")\n",
    "\n",
    "from config import DATA_DIR\n",
    "from graph_types.graph import Graph\n",
    "\n",
    "graph_name = \"prime\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "3b79a1cb",
   "metadata": {},
   "outputs": [],
   "source": [
    "# graph = Graph.load(graph_name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "c2fdf1b6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[('n', 2),\n",
       " ('Hit@1', 0.0),\n",
       " ('Hit@5', 0.5),\n",
       " ('Recall@10', 1.0),\n",
       " ('Recall@20', 1.0),\n",
       " ('Recall@all', 1.0)]"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "logs_dir = DATA_DIR / f\"experiments/{graph_name}/subgraph_explorer\"\n",
    "json_files = sorted([f for f in logs_dir.glob(\"*.json\")], key=lambda x: x.stat().st_ctime)\n",
    "\n",
    "data = []\n",
    "\n",
    "for json_file in json_files:\n",
    "    with open(json_file, \"r\") as f:\n",
    "        log_data = json.load(f)\n",
    "\n",
    "    # Extract key information from each log entry\n",
    "    record = {\n",
    "        \"file_id\": int(json_file.stem),\n",
    "        \"question\": log_data.get(\"question\", \"\"),\n",
    "        \"all_nodes\": log_data.get(\"all_nodes\", []),\n",
    "        \"message_histories\": log_data.get(\"message_histories\", \"\"),\n",
    "        \"starting_nodes_indices\": log_data.get(\"starting_nodes_indices\", []),\n",
    "        \"agent_answer_indices\": log_data.get(\"agent_answer_indices\", []),\n",
    "        \"answer_indices\": log_data.get(\"answer_indices\", []),\n",
    "    }\n",
    "\n",
    "    data.append(record)\n",
    "\n",
    "df = pd.DataFrame(data).reset_index(drop=True)# .sort_values(by=\"file_id\").reset_index(drop=True)\n",
    "\n",
    "df[\"recall@all\"] = df.apply(\n",
    "    lambda row: len(set(row[\"answer_indices\"]).intersection(set(row[\"agent_answer_indices\"])))\n",
    "    / len(set(row[\"answer_indices\"])),\n",
    "    axis=1,\n",
    ")\n",
    "df[\"hit@1\"] = df.apply(\n",
    "    lambda row: (\n",
    "        row[\"agent_answer_indices\"][0] in row[\"answer_indices\"]\n",
    "        if row[\"agent_answer_indices\"]\n",
    "        else False\n",
    "    ),\n",
    "    axis=1,\n",
    ")\n",
    "df[\"hit@5\"] = df.apply(\n",
    "    lambda row: len(set(row[\"answer_indices\"]).intersection(set(row[\"agent_answer_indices\"][:5])))\n",
    "    > 0,\n",
    "    axis=1,\n",
    ")\n",
    "df[\"hit@10\"] = df.apply(\n",
    "    lambda row: len(set(row[\"answer_indices\"]).intersection(set(row[\"agent_answer_indices\"][:10])))\n",
    "    > 0,\n",
    "    axis=1,\n",
    ")\n",
    "df[\"recall@10\"] = df.apply(\n",
    "    lambda row: len(set(row[\"answer_indices\"]).intersection(set(row[\"agent_answer_indices\"][:10])))\n",
    "    / len(set(row[\"answer_indices\"])),\n",
    "    axis=1,\n",
    ")\n",
    "df[\"recall@20\"] = df.apply(\n",
    "    lambda row: len(set(row[\"answer_indices\"]).intersection(set(row[\"agent_answer_indices\"][:20])))\n",
    "    / len(set(row[\"answer_indices\"])),\n",
    "    axis=1,\n",
    ")\n",
    "\n",
    "[\n",
    "    (\"n\", len(df)),\n",
    "    (\"Hit@1\", float(round(df[\"hit@1\"].mean(), 3))),\n",
    "    (\"Hit@5\", float(round(df[\"hit@5\"].mean(), 3))),\n",
    "    (\"Recall@10\", float(round(df[\"recall@10\"].mean(), 3))),\n",
    "    (\"Recall@20\", float(round(df[\"recall@20\"].mean(), 3))),\n",
    "    (\"Recall@all\", float(round(df[\"recall@all\"].mean(), 3))),\n",
    "]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "c60d68a1",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<matplotlib.legend.Legend at 0x139308190>"
      ]
     },
     "execution_count": 4,
     "metadata": {},
     "output_type": "execute_result"
    },
    {
     "data": {
      "image/png": "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",
      "text/plain": [
       "<Figure size 640x480 with 1 Axes>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "plt.plot([df['hit@1'].iloc[:i].mean() for i in range(1, len(df) + 1)], label='Hit@1')\n",
    "plt.axhline(y=df['hit@1'].mean(), color='r', linestyle='--', label='Hit@1 Mean')\n",
    "plt.plot([df['recall@20'].iloc[:i].mean() for i in range(1, len(df) + 1)], label='Recall@20')\n",
    "plt.axhline(y=df['recall@20'].mean(), color='g', linestyle='--', label='Recall@20 Mean')\n",
    "plt.legend()\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "9f8927f8",
   "metadata": {},
   "source": [
    "### Are the answers we don't match mentioned in the reasoning?"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8f35b55c",
   "metadata": {},
   "outputs": [],
   "source": [
    "graph = Graph.load(graph_name)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "ad2e3e63",
   "metadata": {},
   "outputs": [],
   "source": [
    "df['answer_names'] = df['answer_indices'].apply(lambda x: [graph.get_node_by_index(i).name for i in x])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "23ddf53f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "False    21\n",
       "True      7\n",
       "Name: count, dtype: int64"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[df[\"recall@all\"] == 0].apply(\n",
    "    lambda row: all([name in str(row[\"message_histories\"]) for name in row[\"answer_names\"]]), axis=1\n",
    ").value_counts()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "248dc839",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "3"
      ]
     },
     "execution_count": 8,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(df[df['agent_answer_indices'].apply(lambda x: len(x) == 0)])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "19549288",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "np.float64(0.7351428571428571)"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "(df[\"recall@all\"].sum() + 10) / len(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "223cbaff",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Could you provide a list of treatments suitable for someone with mucopolysaccharidosis and Scheie syndrome?'"
      ]
     },
     "execution_count": 54,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['question'][0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0cbb7a6b",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "answer_indices                                      [20647]\n",
       "agent_answer_indices    [17948, 20565, 20649, 17947, 20647]\n",
       "answer_names                                   [Laronidase]\n",
       "Name: 0, dtype: object"
      ]
     },
     "execution_count": 55,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df[['answer_indices', 'agent_answer_indices', 'answer_names']].iloc[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "71df6ab7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['mucopolysaccharidosis', 'Scheie syndrome']"
      ]
     },
     "execution_count": 56,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['starting_nodes_indices'].apply(lambda x: [graph.get_node_by_index(i).name for i in x]).iloc[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "747cb96e",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[\"Galsulfase{'description': 'Galsufase is a variant form of the polymorphic human enzyme N-acetylgalactosamine 4-sulfatase of recombinant DNA origin. Galsulfase is a glycoprotein with a molecular weight of approximately 56 kD. The recombinant protein is comprised of 495 amino acids and contains six asparagine-linked glycosylation sites, four of which carry a bis mannose-6-phosphate manose7 oligosaccharide for specific cellular recognition. Post-translational modification of Cys53 produces the catalytic amino acid residue Ca-formylglycine, which is required for enzyme activity and is conserved in all members of the sulfatase enzyme family.', 'half_life': '9 (6 to 21) minutes during the first week of treatment, 26 (8 to 40) minutes by the 24th week.', 'indication': 'For the treatment of adults and children with Mucopolysaccharidosis VI.', 'mechanism_of_action': 'Galsulfase supplies recombinant-engineered galsulfase, a normal variant form of the polymorphic human enzyme, N-acetylgalactosamine 4-sulfatase. It is a lysosomal hydrolase that catalyzes the cleavage of the sulfate ester from terminal N-acetylgalactosamine 4-sulfate residues of GAG chondroitin 4-sulfate and dermatan sulfate. Increased catabolism of GAG in turn reduces systemic dermatan sulfate accumulation, thereby reducing the primary symptoms of MPS VI.', 'protein_binding': nan, 'pharmacodynamics': 'Mucopolysaccharide storage disorders are caused by the deficiency of specific lysosomal enzymes required for the catabolism of GAG. Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome) is characterized by the absence or marked reduction in N-acetylgalactosamine 4-sulfatase. The sulfatase activity deficiency results in the accumulation of the GAG substrate dermatan sulfate, throughout the body. This accumulation leads to widespread cellular, tissue, and organ dysfunction. Galsulfase is intended to provide an exogenous enzyme that will be taken up into lysosomes and increase the catabolism of GAG. Galsulfase uptake by cells into lysosomes is most likely mediated by the binding of mannose-6-phosphate-terminated oligosaccharide chains of galsulfase to specific mannose-6-phosphate receptors.', 'state': 'Galsulfase is a solid.', 'atc_1': 'Galsulfase is anatomically related to alimentary tract and metabolism.', 'atc_2': 'Galsulfase is in the therapeutic group of other alimentary tract and metabolism products.', 'atc_3': 'Galsulfase is pharmacologically related to other alimentary tract and metabolism products.', 'atc_4': 'The chemical and functional group of  is enzymes.', 'category': 'Galsulfase is part of Alimentary Tract and Metabolism ; Amino Acids, Peptides, and Proteins ; Arylsulfatases ; Carbon-Oxygen Lyases ; Chondroitinases and Chondroitin Lyases ; Chondroitinsulfatases ; Enzymes ; Enzymes and Coenzymes ; Esterases ; Hydrolases ; Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme ; Lyases ; Polysaccharide-Lyases ; Proteins ; Sulfatases.', 'group': 'Galsulfase is approved and investigational.', 'pathway': nan, 'molecular_weight': nan, 'tpsa': nan, 'clogp': nan}\",\n",
       " \"Elosulfase alfa{'description': 'Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim™. The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week.', 'half_life': 'The half-life is week 0: 7.52 min', 'indication': 'Vimizim is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). ', 'mechanism_of_action': 'Mucopolysaccharidoses comprise a group of lysosomal storage disorders caused by the deficiency of specific lysosomal enzymes required for the catabolism of glycosaminoglycans (GAG). Mucopolysaccharidosis IVA (MPS IVA, Morquio A Syndrome) is characterized by the absence or marked reduction in N-acetylgalactosamine-6-sulfatase activity. The sulfatase activity deficiency results in the accumulation of the GAG substrates, KS and C6S, in the lysosomal compartment of cells throughout the body. The accumulation leads to widespread cellular, tissue, and organ dysfunction. Vimizim is intended to provide the exogenous enzyme N-acetylgalactosamine-6-sulfatase that will be taken up into the lysosomes and increase the catabolism of the GAGs KS and C6S. Elosulfase alfa uptake by cells into lysosomes is mediated by the binding of mannose-6-phosphate-terminated oligosaccharide chains of elosulfase alfa to mannose-6-phosphate receptors.', 'protein_binding': nan, 'pharmacodynamics': 'AUC: 238 min x μg/mL, standard deviation 100. ', 'state': 'Elosulfase alfa is a solid.', 'atc_1': 'Elosulfase alfa is anatomically related to alimentary tract and metabolism.', 'atc_2': 'Elosulfase alfa is in the therapeutic group of other alimentary tract and metabolism products.', 'atc_3': 'Elosulfase alfa is pharmacologically related to other alimentary tract and metabolism products.', 'atc_4': 'The chemical and functional group of  is enzymes.', 'category': 'Elosulfase alfa is part of Alimentary Tract and Metabolism ; Carbon-Oxygen Lyases ; Chondroitinases and Chondroitin Lyases ; Enzymes ; Enzymes and Coenzymes ; Esterases ; Hydrolases ; Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme ; Lyases ; Polysaccharide-Lyases ; Recombinant Proteins ; Sulfatases.', 'group': 'Elosulfase alfa is approved and investigational.', 'pathway': nan, 'molecular_weight': nan, 'tpsa': nan, 'clogp': nan}\",\n",
       " \"Vestronidase alfa{'description': 'Vestronidase alfa, or vestronidase alfa-vjbk, is a recombinant human lysosomal beta glucuronidase that is a purified enzyme produced by recombinant DNA technology in a Chinese hamster ovary cell line. The enzyme is a homotetramer consisted of 4 monomers with 629 amino acids, and holds the same amino acid sequence as human beta-glucuronidase (GUS). Vestronidase alfa is an enzyme replacement therapy for the treatment of mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome, which is an inherited, rare genetic metabolic condition that targets a small subset of population. MPS VII is a progressive condition that affects most tissues and organs due to the lack of a lysosomal enzyme called beta-glucuronidase, leading to buildup of toxic metabolites. The disorder is initiated with skeletal abnormalities, including short stature, along with other pathological conditions including enlarged liver and spleen, heart valve abnormalities, and narrowed airways which can lead to lung infections and trouble breathing. Last two conditions are leading causes of fatalities in patients with MPS VII. ', 'half_life': 'After repeated dosing of 4 mg/kg every other week in MPS VII patients, the mean ± standard deviation of the elimination half-life (t1/2) was 155 ± 37 minutes (range: 51 to 213 minutes).', 'indication': 'Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).', 'mechanism_of_action': 'Beta-glucuronidase (GUS) is a lysosomal enzyme responsible for degradation of glucuronate-containing glycosaminoglycan (GAG). Resulting lysosomal storage and GAG accumulation in cells from incomplete metabolic degradation of macromolecules leads to damage to multiple tissues and organs. Vestronidase alfa serves as an exogenous source of GUS enzyme for uptake into cellular lysosomes, which is facilitated by the presence of mannose-6-phosphate (M6P) residues on the oligosaccharide chains of the recombinant enzyme. The chains allow binding of the enzyme to cell surface receptors to promote cellular uptake, and targets the lysosomes to achieve catabolism of accumulated GAGs in affected tissues.', 'protein_binding': nan, 'pharmacodynamics': 'In all patients evaluated, MEPSEVII treatment resulted in reduction of urinary excretion of GAGs including chondroitin sulfate and dermatan sulfate, which was sustained with continued treatment.', 'state': 'Vestronidase alfa is a liquid.', 'atc_1': 'Vestronidase alfa is anatomically related to alimentary tract and metabolism.', 'atc_2': 'Vestronidase alfa is in the therapeutic group of other alimentary tract and metabolism products.', 'atc_3': 'Vestronidase alfa is pharmacologically related to other alimentary tract and metabolism products.', 'atc_4': 'The chemical and functional group of  is enzymes.', 'category': 'Vestronidase alfa is part of Alimentary Tract and Metabolism ; Enzymes ; Lysosomal beta Glucuronidase.', 'group': 'Vestronidase alfa is approved and investigational.', 'pathway': nan, 'molecular_weight': nan, 'tpsa': nan, 'clogp': nan}\",\n",
       " 'Idursulfase{\\'description\\': \\'Idursulfase is a purified form of human iduronate-2-sulfatase, a lysosomal enzyme. Idursulfase is produced by recombinant DNA technology in a human cell line. Idursulfase is an enzyme that hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from the glycosaminoglycans dermatan sulfate and heparan sulfate in the lysosomes of various cell types. Idursulfase is a 525-amino acid glycoprotein with a molecular weight of approximately 76 kilodaltons. The enzyme contains eight asparagine-linked glycosylation sites occupied by complex oligosaccharide structures. The enzyme activity of idursulfase is dependent on the post-translational modification of a specific cysteine to formylglycine.\\', \\'half_life\\': \\'The half-life is 44 &plusmn; 19 minutes\\', \\'indication\\': \\'For the treatment of Hunter syndrome in adults and children ages 5 and older.\\', \\'mechanism_of_action\\': \"Hunter\\'s Syndrome is an X-linked recessive disease caused by insufficient levels of the lysosomal enzyme iduronate-2-sulfatase. This enzyme cleaves the terminal 2-O-sulfate moieties from the glycosaminoglycans (GAG) dermatan sulfate and heparan sulfate. Due to the missing or defective iduronate-2-sulfatase enzyme in patients with Hunter\\'s Syndrome, GAG progressively accumulate in the lysosomes of a variety of cells, leading to cellular engorgement, organomegaly, tissue destruction and organ system dysfunction. Treatment of Hunter\\'s Syndrome patients with idursulfase provides exogenous enzyme for uptake into cellular lysosomes. Targeting of idursulfase to the lysosome occurs by endocytosis from the cell surface. Mannose-6-phosphate (M6P) residues on the oligosaccharide chains allow specific binding of the enzymes to the M6P receptors on the cell surface, leading to cellular internalization of the enzyme, targeting to intracellular lysosomes and subsequent catabolism of accumulated GAG.\", \\'protein_binding\\': nan, \\'pharmacodynamics\\': \\'Idursulfase is a purified form of the lysosomal enzyme human iduronate-2-sulfatase of recombinant DNA origin. It is designed to replace the natural enzyme, increasing catabolism of certain accumulated glycosaminoglycans (GAG), which abnormally accumulate in multiple tissue types in patients with mucopolysaccharidosis II (MPS-II, or Hunter syndrome).\\', \\'state\\': \\'Idursulfase is a solid.\\', \\'atc_1\\': \\'Idursulfase is anatomically related to alimentary tract and metabolism.\\', \\'atc_2\\': \\'Idursulfase is in the therapeutic group of other alimentary tract and metabolism products.\\', \\'atc_3\\': \\'Idursulfase is pharmacologically related to other alimentary tract and metabolism products.\\', \\'atc_4\\': \\'The chemical and functional group of  is enzymes.\\', \\'category\\': \\'Idursulfase is part of Alimentary Tract and Metabolism ; Enzymes ; Enzymes and Coenzymes ; Esterases ; Hydrolases ; Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme ; Sulfatases.\\', \\'group\\': \\'Idursulfase is approved.\\', \\'pathway\\': nan, \\'molecular_weight\\': nan, \\'tpsa\\': nan, \\'clogp\\': nan}',\n",
       " \"Laronidase{'description': 'Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase. It contains 6 N-linked oligosaccharide modification sites.', 'half_life': 'The half-life is 1.5-3.6 hrs', 'indication': 'For the treatment of mucopolysaccharidosis', 'mechanism_of_action': 'Laronidase catalyses the hydrolysis of terminal alpha-L-iduronic acid residues of dermatan sulfate and heparin sulfate.', 'protein_binding': nan, 'pharmacodynamics': 'Laronidase is used to treat mucopolysaccharide storage disorders (specifically mucopolysaccharidosis 1 or Hurlers syndrome) caused by deficiencies of alpha-L-iduronidase. Reduced or absent a-L-iduronidase activity results in the accumulation of the GAG substrates, dermatan sulfate and heparan sulfate, throughout the body and leads to widespread cellular, tissue, and organ dysfunction.', 'state': 'Laronidase is a liquid.', 'atc_1': 'Laronidase is anatomically related to alimentary tract and metabolism.', 'atc_2': 'Laronidase is in the therapeutic group of other alimentary tract and metabolism products.', 'atc_3': 'Laronidase is pharmacologically related to other alimentary tract and metabolism products.', 'atc_4': 'The chemical and functional group of  is enzymes.', 'category': 'Laronidase is part of Alimentary Tract and Metabolism ; Enzymes ; Hydrolytic Lysosomal Glycosaminoglycan-specific Enzyme.', 'group': 'Laronidase is approved.', 'pathway': nan, 'molecular_weight': nan, 'tpsa': nan, 'clogp': nan}\"]"
      ]
     },
     "execution_count": 62,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['agent_answer_indices'].apply(lambda x: [(graph.get_node_by_index(i).name + str(graph.get_node_by_index(i).details)) for i in x]).iloc[0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "5084edbb",
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "8a65b43a",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[[{'role': 'user',\n",
       "   'content': 'Question: Could you provide a list of treatments suitable for someone with mucopolysaccharidosis and Scheie syndrome?\\nYou are standing on node: mucopolysaccharidosis\\n\\nYour objective is to find the nodes that are the answer to the question. \\nFor this, you can\\n- search in the surroundings of this node with `search_in_surroundings` tool. You can also use this to see the neighbors of this node, setting k=1.\\n- find the path that connects this node to another node with the `find_paths` tool\\n- `submit_answer` when you think you found the nodes.\\n\\nConsider searching for keywords and then finding paths to understand the connections between nodes.\\n'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_MRNKixa9mnDn2JLuhKVawtP4',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'search_in_surroundings',\n",
       "      'arguments': '{\"query\": \"treatment\", \"type\": \"drug\", \"k\": 2}'}},\n",
       "    {'id': 'call_e9mEN99QSFVD9O6Wmomqy9dK',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'search_in_surroundings',\n",
       "      'arguments': '{\"query\": \"Scheie\", \"type\": \"disease\", \"k\": 2}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'search_in_surroundings(query=treatment, type=drug, k=2) found:\\n\\nPrimeNode(name=Flunisolide, index=14014, type=drug): ...i-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle ...\\n\\nPrimeNode(name=Medrysone, index=14016, type=drug): ...ology.\", \"half_life\": NaN, \"indication\": \"For the treatment of allergic conjunctivitis, vernal conju...\\n\\nPrimeNode(name=Fluorometholone, index=14017, type=drug): ...ocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions ...\\n\\nPrimeNode(name=Beclomethasone dipropionate, index=14018, type=drug): ...icated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in pat...\\n\\nPrimeNode(name=Betamethasone, index=14019, type=drug): ...teroid family, betamethasone is indicated for the treatment of several inflammatory conditions. As t...\\n\\nPrimeNode(name=Fluocinolone acetonide, index=14021, type=drug): ...th antiseptics and corticosteroids and agents for treatment of hemorrhoids and anal fissures for top...\\n\\nPrimeNode(name=Triamcinolone, index=14023, type=drug): .... Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first li...\\n\\nPrimeNode(name=Mitotane, index=14025, type=drug): ...The half-life is 18-159 days\", \"indication\": \"For treatment of inoperable adrenocortical tumours; Cu...\\n\\nPrimeNode(name=Fludrocortisone, index=14027, type=drug): ...n Addison\\'s disease. It is also indicated for the treatment of salt-losing androgenital syndrome.\", ...\\n\\nPrimeNode(name=Hydrocortisone, index=14028, type=drug): ... and antiinfectives in combination and agents for treatment of hemorrhoids and anal fissures for top...\\n\\nPrimeNode(name=Prednisolone, index=14030, type=drug): ... and antiinfectives in combination and agents for treatment of hemorrhoids and anal fissures for top...\\n\\nPrimeNode(name=Fluocinonide, index=14033, type=drug): ...scription\": \"A topical glucocorticoid used in the treatment of eczema.\", \"half_life\": NaN, \"indicati...\\n\\nPrimeNode(name=Budesonide, index=14034, type=drug): ...e extended release capsules are indicated for the treatment and maintenance of mild to moderate Croh...\\n\\nPrimeNode(name=Ciclesonide, index=14036, type=drug): ...vesco.\", \"half_life\": NaN, \"indication\": \"For the treatment of nasal symptoms associated with season...\\n\\nPrimeNode(name=Fluticasone furoate, index=14038, type=drug): ...casone furoate is indicated as an inhaler for the treatment and management of asthma by prophylaxis....\\n\\n(Showing 15 of 759 results. You may want to refine your search)\\nIf you found what you were looking for you can submit answer.\\nYou can also find connections between the current node `mucopolysaccharidosis` and any of the candidate nodes by using the `find_paths` function.\\n',\n",
       "   'tool_call_id': 'call_MRNKixa9mnDn2JLuhKVawtP4'},\n",
       "  {'role': 'tool',\n",
       "   'content': 'search_in_surroundings(query=Scheie, type=disease, k=2) found:\\n\\nPrimeNode(name=Scheie syndrome, index=27355, type=disease)\\n\\nPrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\n\\n\\n\\nIf you found what you were looking for you can submit answer.\\nYou can also find connections between the current node `mucopolysaccharidosis` and any of the candidate nodes by using the `find_paths` function.\\n',\n",
       "   'tool_call_id': 'call_e9mEN99QSFVD9O6Wmomqy9dK'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_VLjl5qm9SfdbhcJxQxgecZCR',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'find_paths',\n",
       "      'arguments': '{\"dst_node_index\": 27355}'}},\n",
       "    {'id': 'call_2RkUR2dH2kQ7s3N2Iy38ZlSJ',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'find_paths',\n",
       "      'arguments': '{\"dst_node_index\": 27894}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'The paths between the current node `PrimeNode(name=mucopolysaccharidosis, index=27304, type=disease)` and `PrimeNode(name=Scheie syndrome, index=27355, type=disease)` are\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Constrictive median neuropathy, index=89177, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Thick vermilion border, index=22209, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Autosomal recessive inheritance, index=26180, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Limitation of joint mobility, index=22727, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Intellectual disability, index=22675, type=effect/phenotype) <-> phenotype absent <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Retinal degeneration, index=22395, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Cervical cord compression, index=85128, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> parent-child <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype absent <-> PrimeNode(name=Intellectual disability, index=22675, type=effect/phenotype) <-> phenotype absent <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Mucopolysacchariduria, index=23035, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Full cheeks, index=84573, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Genu valgum, index=26936, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Wide mouth, index=84525, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Wide nose, index=84620, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> indication <-> PrimeNode(name=Laronidase, index=20647, type=drug) <-> indication <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> parent-child <-> PrimeNode(name=syndromic disease, index=35690, type=disease) <-> parent-child <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> associated with <-> PrimeNode(name=IDUA, index=2475, type=gene/protein) <-> associated with <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Coarse facial features, index=22282, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Splenomegaly, index=24143, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Everted lower lip vermilion, index=84556, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Depressed nasal bridge, index=86198, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Dysostosis multiplex, index=84766, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Corneal opacity, index=22373, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Joint stiffness, index=23937, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Pes cavus, index=24464, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Hepatomegaly, index=24199, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Mandibular prognathia, index=84579, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Short neck, index=84633, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Scheie syndrome, index=27355, type=disease)\\nconsider if any of these paths can help you answer the question\\n',\n",
       "   'tool_call_id': 'call_VLjl5qm9SfdbhcJxQxgecZCR'},\n",
       "  {'role': 'tool',\n",
       "   'content': 'The paths between the current node `PrimeNode(name=mucopolysaccharidosis, index=27304, type=disease)` and `PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)` are\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> indication <-> PrimeNode(name=Laronidase, index=20647, type=drug) <-> indication <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Limitation of joint mobility, index=22727, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Thick vermilion border, index=22209, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Corneal opacity, index=22373, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> parent-child <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Recurrent respiratory infections, index=23230, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Short stature, index=22488, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Cardiomyopathy, index=22824, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Kyphosis, index=23222, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Abnormality of the tonsils, index=25333, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> associated with <-> PrimeNode(name=IDUA, index=2475, type=gene/protein) <-> associated with <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Hernia, index=22466, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Splenomegaly, index=24143, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Hepatomegaly, index=24199, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Abnormal heart valve morphology, index=22825, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Hirsutism, index=23072, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Abnormal vertebral morphology, index=23311, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Coarse facial features, index=22282, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Depressed nasal bridge, index=86198, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> parent-child <-> PrimeNode(name=lysosomal disease with hypertrophic cardiomyopathy, index=38633, type=disease) <-> parent-child <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> parent-child <-> PrimeNode(name=syndromic disease, index=35690, type=disease) <-> parent-child <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Autosomal recessive inheritance, index=26180, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Joint stiffness, index=23937, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Generalized hirsutism, index=85098, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Dysostosis multiplex, index=84766, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Abnormal pyramidal sign, index=23495, type=effect/phenotype) <-> phenotype present <-> PrimeNode(name=Hurler-Scheie syndrome, index=27894, type=disease)\\nconsider if any of these paths can help you answer the question\\n',\n",
       "   'tool_call_id': 'call_2RkUR2dH2kQ7s3N2Iy38ZlSJ'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_fHpXGjPhjAI8JiBaBXHAy1Oc',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'add_to_answer',\n",
       "      'arguments': '{\"answer_node_names\":[\"Laronidase\"],\"answer_node_indices\":[20647]}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'Added the following nodes to the answer:PrimeNode(name=Laronidase, index=20647, type=drug)',\n",
       "   'tool_call_id': 'call_fHpXGjPhjAI8JiBaBXHAy1Oc'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_MzPHGbzwzYFKikVy0Ic3CYLa',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'search_in_surroundings',\n",
       "      'arguments': '{\"query\":\"treatment\",\"type\":\"drug\",\"k\":2}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'search_in_surroundings(query=treatment, type=drug, k=2) found:\\n\\nPrimeNode(name=Flunisolide, index=14014, type=drug): ...i-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle ...\\n\\nPrimeNode(name=Medrysone, index=14016, type=drug): ...ology.\", \"half_life\": NaN, \"indication\": \"For the treatment of allergic conjunctivitis, vernal conju...\\n\\nPrimeNode(name=Fluorometholone, index=14017, type=drug): ...ocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions ...\\n\\nPrimeNode(name=Beclomethasone dipropionate, index=14018, type=drug): ...icated for oral inhalation use in the maintenance treatment of asthma as prophylactic therapy in pat...\\n\\nPrimeNode(name=Betamethasone, index=14019, type=drug): ...teroid family, betamethasone is indicated for the treatment of several inflammatory conditions. As t...\\n\\nPrimeNode(name=Fluocinolone acetonide, index=14021, type=drug): ...th antiseptics and corticosteroids and agents for treatment of hemorrhoids and anal fissures for top...\\n\\nPrimeNode(name=Triamcinolone, index=14023, type=drug): .... Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first li...\\n\\nPrimeNode(name=Mitotane, index=14025, type=drug): ...The half-life is 18-159 days\", \"indication\": \"For treatment of inoperable adrenocortical tumours; Cu...\\n\\nPrimeNode(name=Fludrocortisone, index=14027, type=drug): ...n Addison\\'s disease. It is also indicated for the treatment of salt-losing androgenital syndrome.\", ...\\n\\nPrimeNode(name=Hydrocortisone, index=14028, type=drug): ... and antiinfectives in combination and agents for treatment of hemorrhoids and anal fissures for top...\\n\\nPrimeNode(name=Prednisolone, index=14030, type=drug): ... and antiinfectives in combination and agents for treatment of hemorrhoids and anal fissures for top...\\n\\nPrimeNode(name=Fluocinonide, index=14033, type=drug): ...scription\": \"A topical glucocorticoid used in the treatment of eczema.\", \"half_life\": NaN, \"indicati...\\n\\nPrimeNode(name=Budesonide, index=14034, type=drug): ...e extended release capsules are indicated for the treatment and maintenance of mild to moderate Croh...\\n\\nPrimeNode(name=Ciclesonide, index=14036, type=drug): ...vesco.\", \"half_life\": NaN, \"indication\": \"For the treatment of nasal symptoms associated with season...\\n\\nPrimeNode(name=Fluticasone furoate, index=14038, type=drug): ...casone furoate is indicated as an inhaler for the treatment and management of asthma by prophylaxis....\\n\\n(Showing 15 of 759 results. You may want to refine your search)\\nIf you found what you were looking for you can submit answer.\\nYou can also find connections between the current node `mucopolysaccharidosis` and any of the candidate nodes by using the `find_paths` function.\\n',\n",
       "   'tool_call_id': 'call_MzPHGbzwzYFKikVy0Ic3CYLa'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_eiGRHZqHM1ntY1xu4MgB1HSJ',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'search_in_surroundings',\n",
       "      'arguments': '{\"query\":\"therapy\",\"type\":\"drug\",\"k\":2}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'search_in_surroundings(query=therapy, type=drug, k=2) found:\\n\\nPrimeNode(name=Flunisolide, index=14014, type=drug): ...maintenance treatment of asthma as a prophylactic therapy.\", \"mechanism_of_action\": \"Flunisolide is ...\\n\\nPrimeNode(name=Beclomethasone dipropionate, index=14018, type=drug): ...e maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. The ...\\n\\nPrimeNode(name=Betamethasone, index=14019, type=drug): ...f several inflammatory conditions. As topical monotherapy, betamethasone is indicated to relieve pru...\\n\\nPrimeNode(name=Fludrocortisone, index=14027, type=drug): ...udrocortisone is indicated as partial replacement therapy for primary or secondary adrenocortical in...\\n\\nPrimeNode(name=Hydrocortisone, index=14028, type=drug): ...nules of hydrocortisone are used as a replacement therapy for Adrenocortical Insufficiency (AI) in c...\\n\\nPrimeNode(name=Budesonide, index=14034, type=drug): ...udesonide products are indicated for prophylactic therapy in asthma and reducing exacerbations of CO...\\n\\nPrimeNode(name=Liothyronine, index=14059, type=drug): ...othyronine is in the therapeutic group of thyroid therapy.\", \"atc_3\": \"Liothyronine is pharmacologic...\\n\\nPrimeNode(name=Levothyroxine, index=14060, type=drug): ...tion\": \"Levothyroxine is indicated as replacement therapy in primary (thyroidal), secondary (pituita...\\n\\nPrimeNode(name=Diclofenac, index=14061, type=drug): ...c, like other NSAIDs, is often used as first line therapy for acute and chronic pain and inflammatio...\\n\\nPrimeNode(name=Lovastatin, index=14135, type=drug): ...step in the biosynthetic pathway for cholesterol, therapy with lovastatin would not be expected to c...\\n\\nPrimeNode(name=Benzatropine, index=14139, type=drug): ...pine is indicated to be used as an adjunct in the therapy of all forms of parkinsonism. It can also ...\\n\\nPrimeNode(name=Ziprasidone, index=14140, type=drug): ...proved for the treatment of schizophrenia, as monotherapy for acute treatment of manic or mixed epis...\\n\\nPrimeNode(name=Topiramate, index=14144, type=drug): ...in combination with for chronic weight management therapy in adults. \", \"half_life\": \"The eliminatio...\\n\\nPrimeNode(name=Atomoxetine, index=14148, type=drug): ... (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropr...\\n\\nPrimeNode(name=Acetaminophen, index=14154, type=drug): ...lgesic worldwide and is recommended as first-line therapy in pain conditions by the World Health Org...\\n\\n(Showing 15 of 290 results. You may want to refine your search)\\nIf you found what you were looking for you can submit answer.\\nYou can also find connections between the current node `mucopolysaccharidosis` and any of the candidate nodes by using the `find_paths` function.\\n',\n",
       "   'tool_call_id': 'call_eiGRHZqHM1ntY1xu4MgB1HSJ'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_eQWIlKoIlLGspOEu6u5wFAPt',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'search_in_surroundings',\n",
       "      'arguments': '{\"query\":\"enzymes\",\"type\":\"drug\",\"k\":2}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'search_in_surroundings(query=enzymes, type=drug, k=2) found:\\n\\nPrimeNode(name=Fluocinonide, index=14033, type=drug): ...ease of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, ...\\n\\nPrimeNode(name=Hydrocortisone acetate, index=14042, type=drug): ...ease of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator, ...\\n\\nPrimeNode(name=Diclofenac, index=14061, type=drug): ...\"Diclofenac inhibits cyclooxygenase-1 and -2, the enzymes responsible for production of prostaglandi...\\n\\nPrimeNode(name=Cisplatin, index=14186, type=drug): ..., resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated...\\n\\nPrimeNode(name=Methotrexate, index=14194, type=drug): ...xate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This...\\n\\nPrimeNode(name=Sulindac, index=14204, type=drug): ... _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that ...\\n\\nPrimeNode(name=Imatinib, index=14207, type=drug): ...specific inhibitor of a number of tyrosine kinase enzymes. Chronic myelogenous leukemia is associate...\\n\\nPrimeNode(name=Efavirenz, index=14209, type=drug): ...ssary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle th...\\n\\nPrimeNode(name=Irinotecan, index=14231, type=drug): ...ge produced during DNA synthesis when replication enzymes interact with the ternary complex formed b...\\n\\nPrimeNode(name=Naproxen, index=14238, type=drug): ...it\\'s clinical effects by blocking COX-1 and COX-2 enzymes leading to decreased prostaglandin synthes...\\n\\nPrimeNode(name=Meloxicam, index=14242, type=drug): ... prostaglandin synthetase (cylooxygenase 1 and 2) enzymes leading to a decreased synthesis of prosta...\\n\\nPrimeNode(name=Didanosine, index=14256, type=drug): ...tabolized intracellularly by a series of cellular enzymes to its active moiety, dideoxyadenosine tri...\\n\\nPrimeNode(name=Zalcitabine, index=14264, type=drug): ...ate (ddCTP), by the sequential action of cellular enzymes. ddCTP interferes with viral RNA-directed ...\\n\\nPrimeNode(name=Gatifloxacin, index=14285, type=drug): ...lone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was fi...\\n\\nPrimeNode(name=Benzylpenicillin, index=14288, type=drug): ...is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that pe...\\n\\n(Showing 15 of 117 results. You may want to refine your search)\\nIf you found what you were looking for you can submit answer.\\nYou can also find connections between the current node `mucopolysaccharidosis` and any of the candidate nodes by using the `find_paths` function.\\n',\n",
       "   'tool_call_id': 'call_eQWIlKoIlLGspOEu6u5wFAPt'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_lVjNOaL7TaOgcBWPSpmkiZAW',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'search_in_surroundings',\n",
       "      'arguments': '{\"query\":\"enzyme replacement\",\"type\":\"drug\",\"k\":2}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'search_in_surroundings(query=enzyme replacement, type=drug, k=2) found:\\n\\nPrimeNode(name=Miglustat, index=17303, type=drug): ...only used for patients who cannot be treated with enzyme replacement therapy with imiglucerase. Migl...\\n\\nPrimeNode(name=Vestronidase alfa, index=20649, type=drug): ...beta-glucuronidase (GUS). Vestronidase alfa is an enzyme replacement therapy for the treatment of mu...\\n\\n\\n\\nIf you found what you were looking for you can submit answer.\\nYou can also find connections between the current node `mucopolysaccharidosis` and any of the candidate nodes by using the `find_paths` function.\\n',\n",
       "   'tool_call_id': 'call_lVjNOaL7TaOgcBWPSpmkiZAW'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_cYSeXoUtmehE61J7ZrMXQgCe',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'find_paths',\n",
       "      'arguments': '{\"dst_node_index\": 17303}'}},\n",
       "    {'id': 'call_5CTf14bcOiy3eI0VpfjXQTzL',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'find_paths',\n",
       "      'arguments': '{\"dst_node_index\": 20649}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'The paths between the current node `PrimeNode(name=mucopolysaccharidosis, index=27304, type=disease)` and `PrimeNode(name=Miglustat, index=17303, type=drug)` are\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Seizure, index=23000, type=effect/phenotype) <-> side effect <-> PrimeNode(name=Miglustat, index=17303, type=drug)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Gait disturbance, index=22998, type=effect/phenotype) <-> side effect <-> PrimeNode(name=Miglustat, index=17303, type=drug)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Visual impairment, index=22380, type=effect/phenotype) <-> side effect <-> PrimeNode(name=Miglustat, index=17303, type=drug)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Muscle weakness, index=22323, type=effect/phenotype) <-> side effect <-> PrimeNode(name=Miglustat, index=17303, type=drug)\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> phenotype present <-> PrimeNode(name=Paresthesia, index=25644, type=effect/phenotype) <-> side effect <-> PrimeNode(name=Miglustat, index=17303, type=drug)\\nconsider if any of these paths can help you answer the question\\n',\n",
       "   'tool_call_id': 'call_cYSeXoUtmehE61J7ZrMXQgCe'},\n",
       "  {'role': 'tool',\n",
       "   'content': 'The paths between the current node `PrimeNode(name=mucopolysaccharidosis, index=27304, type=disease)` and `PrimeNode(name=Vestronidase alfa, index=20649, type=drug)` are\\nPrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> indication <-> PrimeNode(name=Vestronidase alfa, index=20649, type=drug)\\nconsider if any of these paths can help you answer the question\\n',\n",
       "   'tool_call_id': 'call_5CTf14bcOiy3eI0VpfjXQTzL'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_bkSScfl8lHx8UU1ey6210EeE',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'add_to_answer',\n",
       "      'arguments': '{\"answer_node_names\":[\"Vestronidase alfa\"],\"answer_node_indices\":[20649]}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'Added the following nodes to the answer:PrimeNode(name=Vestronidase alfa, index=20649, type=drug)',\n",
       "   'tool_call_id': 'call_bkSScfl8lHx8UU1ey6210EeE'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_jgGNXTgZLCUZPxgIU8CiuyGG',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'search_in_surroundings',\n",
       "      'arguments': '{\"query\":\"Hurler\",\"type\":\"drug\",\"k\":2}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'search_in_surroundings(query=Hurler, type=drug, k=2) found:\\n\\nPrimeNode(name=Laronidase, index=20647, type=drug): ...isorders (specifically mucopolysaccharidosis 1 or Hurlers syndrome) caused by deficiencies of alpha-...\\n\\n\\n\\nIf you found what you were looking for you can submit answer.\\nYou can also find connections between the current node `mucopolysaccharidosis` and any of the candidate nodes by using the `find_paths` function.\\n',\n",
       "   'tool_call_id': 'call_jgGNXTgZLCUZPxgIU8CiuyGG'}],\n",
       " [{'role': 'user',\n",
       "   'content': 'Question: Could you provide a list of treatments suitable for someone with mucopolysaccharidosis and Scheie syndrome?\\nYou are standing on node: Scheie syndrome\\n\\nYour objective is to find the nodes that are the answer to the question. \\nFor this, you can\\n- search in the surroundings of this node with `search_in_surroundings` tool. You can also use this to see the neighbors of this node, setting k=1.\\n- find the path that connects this node to another node with the `find_paths` tool\\n- `submit_answer` when you think you found the nodes.\\n\\nConsider searching for keywords and then finding paths to understand the connections between nodes.\\n'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_Ciq24el1uIRmLcn5Hng2ceTc',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'search_in_surroundings',\n",
       "      'arguments': '{\"type\":\"drug\",\"k\":1}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'search_in_surroundings(type=drug, k=1) found:\\n\\nPrimeNode(name=Laronidase, index=20647, type=drug)\\n\\n\\n\\nIf you found what you were looking for you can submit answer.\\nYou can also find connections between the current node `Scheie syndrome` and any of the candidate nodes by using the `find_paths` function.\\n',\n",
       "   'tool_call_id': 'call_Ciq24el1uIRmLcn5Hng2ceTc'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_DrI4wH3n0iNTlzkexLpcfaAf',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'add_to_answer',\n",
       "      'arguments': '{\"answer_node_names\":[\"Laronidase\"],\"answer_node_indices\":[20647]}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'Added the following nodes to the answer:PrimeNode(name=Laronidase, index=20647, type=drug)',\n",
       "   'tool_call_id': 'call_DrI4wH3n0iNTlzkexLpcfaAf'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_1r5PzyXTITtUt6wsKxM8tHKi',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'search_in_surroundings',\n",
       "      'arguments': '{\"query\":\"mucopolysaccharidosis\",\"type\":\"drug\",\"k\":2}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'search_in_surroundings(query=mucopolysaccharidosis, type=drug, k=2) found:\\n\\nPrimeNode(name=Idursulfase, index=17947, type=drug): ...umulate in multiple tissue types in patients with mucopolysaccharidosis II (MPS-II, or Hunter syndro...\\n\\nPrimeNode(name=Galsulfase, index=17948, type=drug): ...\": \"For the treatment of adults and children with Mucopolysaccharidosis VI.\", \"mechanism_of_action\":...\\n\\nPrimeNode(name=Elosulfase alfa, index=20565, type=drug): ...(GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A...\\n\\nPrimeNode(name=Laronidase, index=20647, type=drug): ...1.5-3.6 hrs\", \"indication\": \"For the treatment of mucopolysaccharidosis\", \"mechanism_of_action\": \"La...\\n\\nPrimeNode(name=Vestronidase alfa, index=20649, type=drug): ...n enzyme replacement therapy for the treatment of mucopolysaccharidosis type VII (MPS VII), also kno...\\n\\n\\n\\nIf you found what you were looking for you can submit answer.\\nYou can also find connections between the current node `Scheie syndrome` and any of the candidate nodes by using the `find_paths` function.\\n',\n",
       "   'tool_call_id': 'call_1r5PzyXTITtUt6wsKxM8tHKi'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_kDBVQVbL6SRD1BudMs6jqNAj',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'add_to_answer',\n",
       "      'arguments': '{\"answer_node_names\":[\"Idursulfase\",\"Galsulfase\",\"Elosulfase alfa\",\"Vestronidase alfa\"],\"answer_node_indices\":[17947,17948,20565,20649]}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'Added the following nodes to the answer:PrimeNode(name=Idursulfase, index=17947, type=drug),PrimeNode(name=Galsulfase, index=17948, type=drug),PrimeNode(name=Elosulfase alfa, index=20565, type=drug),PrimeNode(name=Vestronidase alfa, index=20649, type=drug)',\n",
       "   'tool_call_id': 'call_kDBVQVbL6SRD1BudMs6jqNAj'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_GQwLMKK0f3lGhsaAfZcM1Y0s',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'find_paths',\n",
       "      'arguments': '{\"dst_node_index\":17947}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'The paths between the current node `PrimeNode(name=Scheie syndrome, index=27355, type=disease)` and `PrimeNode(name=Idursulfase, index=17947, type=drug)` are\\nPrimeNode(name=Scheie syndrome, index=27355, type=disease) <-> parent-child <-> PrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> indication <-> PrimeNode(name=Idursulfase, index=17947, type=drug)\\nconsider if any of these paths can help you answer the question\\n',\n",
       "   'tool_call_id': 'call_GQwLMKK0f3lGhsaAfZcM1Y0s'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_awX8n1a0PQzJHzgOTJxSildk',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'find_paths',\n",
       "      'arguments': '{\"dst_node_index\":17948}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'The paths between the current node `PrimeNode(name=Scheie syndrome, index=27355, type=disease)` and `PrimeNode(name=Galsulfase, index=17948, type=drug)` are\\nPrimeNode(name=Scheie syndrome, index=27355, type=disease) <-> parent-child <-> PrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> indication <-> PrimeNode(name=Galsulfase, index=17948, type=drug)\\nconsider if any of these paths can help you answer the question\\n',\n",
       "   'tool_call_id': 'call_awX8n1a0PQzJHzgOTJxSildk'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_P81oYGZyn2BgDxqjQxy75bX3',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'find_paths',\n",
       "      'arguments': '{\"dst_node_index\":20565}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'The paths between the current node `PrimeNode(name=Scheie syndrome, index=27355, type=disease)` and `PrimeNode(name=Elosulfase alfa, index=20565, type=drug)` are\\nPrimeNode(name=Scheie syndrome, index=27355, type=disease) <-> parent-child <-> PrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> indication <-> PrimeNode(name=Elosulfase alfa, index=20565, type=drug)\\nconsider if any of these paths can help you answer the question\\n',\n",
       "   'tool_call_id': 'call_P81oYGZyn2BgDxqjQxy75bX3'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_w4f9Be8sI1yP1QwTqeyf2vFf',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'find_paths',\n",
       "      'arguments': '{\"dst_node_index\":20649}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'The paths between the current node `PrimeNode(name=Scheie syndrome, index=27355, type=disease)` and `PrimeNode(name=Vestronidase alfa, index=20649, type=drug)` are\\nPrimeNode(name=Scheie syndrome, index=27355, type=disease) <-> parent-child <-> PrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> indication <-> PrimeNode(name=Vestronidase alfa, index=20649, type=drug)\\nconsider if any of these paths can help you answer the question\\n',\n",
       "   'tool_call_id': 'call_w4f9Be8sI1yP1QwTqeyf2vFf'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_0QRghId50zo1b8qWatNnYrnc',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'find_paths',\n",
       "      'arguments': '{\"dst_node_index\":20647}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'The paths between the current node `PrimeNode(name=Scheie syndrome, index=27355, type=disease)` and `PrimeNode(name=Laronidase, index=20647, type=drug)` are\\nPrimeNode(name=Scheie syndrome, index=27355, type=disease) <-> parent-child <-> PrimeNode(name=mucopolysaccharidosis, index=27304, type=disease) <-> indication <-> PrimeNode(name=Laronidase, index=20647, type=drug)\\nPrimeNode(name=Scheie syndrome, index=27355, type=disease) <-> indication <-> PrimeNode(name=Laronidase, index=20647, type=drug)\\nconsider if any of these paths can help you answer the question\\n',\n",
       "   'tool_call_id': 'call_0QRghId50zo1b8qWatNnYrnc'},\n",
       "  {'role': 'assistant',\n",
       "   'tool_calls': [{'id': 'call_0JYefidezZlXsj7QGL7tAMy9',\n",
       "     'type': 'function',\n",
       "     'function': {'name': 'add_to_answer',\n",
       "      'arguments': '{\"answer_node_names\":[\"Laronidase\"],\"answer_node_indices\":[20647]}'}}]},\n",
       "  {'role': 'tool',\n",
       "   'content': 'Added the following nodes to the answer:PrimeNode(name=Laronidase, index=20647, type=drug)',\n",
       "   'tool_call_id': 'call_0JYefidezZlXsj7QGL7tAMy9'}]]"
      ]
     },
     "execution_count": 63,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "df['message_histories'][0]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "9cf5f5ea",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
